



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :  G01N 33/543		A1	(11) International Publication Number: <b>WO 90/05306</b>  (43) International Publication Date: 17 May 1990 (17.05.90)
(21) International Application Number: PCT/SE89/00644  (22) International Filing Date: 9 November 1989 (09.11.89)  (30) Priority data: 8804074-6 10 November 1988 (10.11.88) SE 8902043-2 5 June 1989 (05.06.89) SE		(74) Agents: SVANSTRÖM, Pär et al.; Pharmacia AB, S-751 82 Uppsala (SE).  (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.  Published <i>With international search report.</i>	
(71) Applicant (for all designated States except US): PHARMA-CIA AB [SE/SE]; S-751 82 Uppsala (SE).  (72) Inventors; and (75) Inventors/Applicants (for US only) : MALMQVIST, Magnus [SE/SE]; Rörbäcksvägen 39, S-752 57 Uppsala (SE). KARLSSON, Robert [SE/SE]; Torbjörnsgatan 28, S-753 35 Uppsala (SE). LARSSON, Anita [SE/SE]; Järpvägen 27, S-756 53 Uppsala (SE). SJÖDAHL, Jörgen [SE/SE]; Persikovägen 1, S-741 00 Knivsta (SE).			
(54) Title: CHARACTERIZING MACROMOLECULES INTERACTING WITH AT LEAST TWO LIGANDS ON A SENSOR			
(57) Abstract <p>A method of characterizing a macromolecule by studying its interactions with ligands comprises the determination of the mutual influence of ligand interactions by, after the macromolecule has interacted with at least one ligand, contacting the macromolecule with at least one additional ligand, either the macromolecule or the additional ligand or ligands having been bound to a sensor surface, determining interaction by detecting a consequential change in the physico-chemical properties of the sensor surface, and on the basis of the determined mutual dependence between the ligand interactions discriminating between epitopes of the macromolecule and mapping their relative positions.</p>			

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

CHARACTERIZING MACROMOLECULES INTERACTING  
WITH AT LEAST TWO LIGANDS ON A SENSOR.

The present invention relates to the characterization of macromolecules, particularly proteins, and more particularly to a method of gaining structural information about macromolecules by studying their reactions with various ligands.

The characterization of proteins is today done mainly by two groups of techniques, viz., on one hand, composition informative techniques (aminoacid analysis, sequence analysis, spectrophotometry, massspectrometry), which all give the contents of chemical entities but no information about where these are located in the space, and, on the other hand, spacial structural methods (X-ray crystallography, NMR, cryo-electron microscopy, scanning electron tunneling microscopy), which depending on the particular method will provide various degrees of structural information. By X-ray crystallography the total spacial structure is certainly obtained, but the method requires transformation of the proteins into a crystalline form, which generally is difficult, and the method is further very time-consuming and laborious. It is worth mentioning that presently there are only about 400 proteins whose structures have been determined by X-ray crystallography with atomic resolution. The structural information with high resolution is obtained also by NMR, requiring the protein to be in solution. The resolution has hitherto been limited by the magnetic field of the apparatus, which magnetic fields cannot be unlimitedly strong, and by the size and the solubility of the proteins. Both NMR and X-ray crystallography additionally require pure proteins of a high quality and relatively large amounts thereof. Cryo-electron microscopy may provide surface structural information on protein in solid form by visual analysis, and scanning electron tunneling microscopy may possibly provide some information on protein in solid form. In summary these techniques for obtaining structural information about proteins are thus either complicated and time-consuming or will only provide limited information.

Structural information about proteins has also been

obtained by immunological methods of analysis by means of antibodies specifically directed against a domain or region of the protein in question. For example, Furie B. et al. describe in Methods in Enzymology 84 (1982) 60-63 a study of 5 conformational changes of prothrombin and Factor X by means of antibodies directed against specific determinants on the protein surface. Epitope mapping (i.e. determination of epitopes on the surface of a macromolecule) of human  $\alpha_2$ -macroglobulin by means of monoclonal antibodies and blotting 10 technique is described by Van Leuven et al. in J. Immunol. 90 (1986) 125-130, while Mazza M.M and Retegui L.A. in Molec. Immun. 26 (1989) 231-240 describe epitope mapping of human growth hormon (hGH) by means of monoclonal antibodies and solid-phase RIA technique.

15 Recently optical methods for determining changes in the surface layer of a solid surface have begun to come into use in chemical and biochemical connections, e.g., for measuring the adsorption of tensides and proteins to various surfaces. Among these optical methods are ellipsometry and surface 20 plasmon resonance technology (SPR). Ellipsometry is an old optical method rendering it possible to measure the refractive index of reflecting materials by measuring the change in mutual amplitude and phase relationships that the components of elliptic polarized light undergo when reflected against 25 the surface. Upon adsorption of various substances to the surface, the amount adsorbed to the surface may be calculated as well as the thickness of the adsorbed layer. Surface plasmon resonance technique may in somewhat simplified terms be said to be a technique according to which changes in the 30 refractive index of a layer close to a thin free-electron metal film are detected by way of the change of the intensity of a reflected p-polarized light beam that is caused by these refractive index changes (see, e.g. Raether H., I Physics of Thin Films, Ed. Hass G., Francombe M., and Hoffman R., Academic Press, New York, pages 145-261 (1977)). Hereinafter some 35 publications will be described in which these techniques have been utilized in the chemical or biochemical field.

Cullen et al. describe in Biosensors 3 (1987/88) 211-

225 the use of SPR techniques to detect immuno-complex formation in two model biochemical systems, in which human immuno-globulin G or the immunoglobulin fraction of sheep antiserum was physically adsorbed to a gold-coated diffraction grating.

5 Affinity purified goat anti-human-IgG or human serum albumin, respectively, was subsequently specifically bound by immuno-complex formation, and the binding reactions could be followed with respect to time.

Daniels P. B. et al. describe in Sensors and Actuators, 10 15 (1988) 11-18, experiments where a concentration dependent change in surface plasmon resonance is obtained for the two systems avidin-immobilized biotin and alpha-feto protein immobilized antibody-antigen, which indicates the possibility of using SPR for a direct immunochemical analysis in solution.

15 Elwing H. et al. describe in J. Colloid Interface Sci., 125 (1988) 139-145, ellipsometric determination of conformational changes of the complement factor C3 adsorbed to hydrophilic and hydrophobic surfaces by means of antibodies directed against epitopes hidden in the native molecule.

20 Jönsson U. et al. describe in J. Colloid Interface Sci. 90 (1982) 148 - 163, the use of ellipsometry to study the adsorption of human fibronectin (HFN) to solid surfaces. Conformational changes of the protein upon adsorption were 25 revealed by studying the interactions of the adsorbed protein with anti-HFN and concanavalin, respectively.

30 In Horrisberger M., Biochim. Biophys. Acta 632 (1980) 298 - 309, is described the use of ellipsometry for the investigation of the interaction of lectins with films of polysaccharides, glycopeptides and glycoproteins applied to a glass surface.

35 Mandenius, C.F. et al. describe in Anal. Biochem. 137 (1984) 106-114 the use of ellipsometry to study the interaction between proteins and cells with affinity ligands covalently coupled to silicon surfaces. The specific systems studied were concanavalin A-Saccharomyces cerevisiae-cells, immunoglobulin G-Staphylococcus aureus-cells and NAD-ana-logue-lactate dehydrogenase.

EP-B-26 215 discloses the use of a piezoelectric quartz crystal oscillator having an adsorbed layer of antigen thereon for determining the amount of an antigen specific antibody in a fluid sample.

5 Several of the above mentioned publications may quite principally be said to be examples of biosensor technology. A biosensor may be defined as a sensor capable of measuring the presence of biological molecules or particles in a sample and consists of a receptor for molecular recognition and a  
10 transducer. A group or type of biosensors is based upon detecting the changes occurring in the properties of a surface layer by the interaction of the receptor with the surrounding medium, such as by means of the above mentioned SPR and ellipsometry methods. Until now, however, biosensors in the  
15 proper sense have exclusively been used to detect or determine the concentration of a substance in a sample.

The present invention relates to the use of biosensor technology for a completely different purpose, viz. the characterization of macromolecules, such as proteins, with  
20 regard to exposed structural elements by studying the interactions of the macromolecules with various ligands and their mutual influence upon each other.

Before the invention is described in more detail part of the terminology used in connection with the definition of  
25 the invention will be explained.

The term macromolecule does not mean any real size limitation for the molecules it is intended to comprise, but generally refers to all large-sized molecules for which it is of interest to establish structural domains of the molecule.  
30 Examples are proteins (also including glycoproteins, lipoproteins, etc.), polypeptides, carbohydrates, lectins, polymers, DNA, RNA, etc., and the macromolecules may be natural as well as prepared synthetically.

Epitope refers to a defined surface-exposed structural element on a macromolecule. Certain epitopes - antigenic determinants - are characterized by their ability to bind to antibody molecules. Other epitopes may bind to other types of molecules. For example, glycosylated parts of a protein bind

to certain lectins, certain exposed amino-acid residues chelate with metal ions, other epitopes constitute the bio-functional structure of the molecule and bind, e.g., to receptors or constitute a receptor binding site. The examples 5 may easily be multiplied.

Ligand is a chemical compound which can interact with an epitope of a macromolecule. The ligand may itself exhibit one or more epitopes, through which the interactions take place. The ligand may, but need not, be a macromolecule. As 10 examples of ligands may be mentioned natural ligands such as substrate to enzyme and signal substance to receptor, chelating structures to amino-acid residues on a surface, borates (react with sugars), aromates (bind to aromatic regions), antibodies (against antigenic epitope) and lectins (for 15 reaction with a glycosylic epitope).

Sensor surface herein refers to a sensing or measurement surface or area of, or analogous to the type that may be present in a biosensor (according to the definition given above) based upon the detection of changes in the physico-chemical properties of a surface layer. Such surfaces will be 20 discussed in more detail below.

The present invention thus relates to a method of characterizing a macromolecule by studying its interactions with ligands, and is characterized in that it comprises determination 25 of the mutual influence of ligand interactions by, after the macromolecule has interacted with at least one ligand, contacting the macromolecule with at least one additional ligand, either the macromolecule or the additional ligand(s) having been bound to a sensor surface, determining 30 interaction by detecting a consequential change in the physico-chemical properties of the sensor surface, and on the basis of the determined mutual dependence between the ligand interactions discriminating between epitopes of the macromolecule and mapping their relative positions.

35 By this method, due to the use of "biosensor" technique, an extraordinarily rapid and simple determination of surface-structural elements of the macromolecule is achieved. Further, the "biosensor"-based detection of the ligand inter-

actions implies that the ligand or the macromolecule need not be labelled with detectable markers, since the molecule itself contributes to physico-chemical changes on the sensor surface. Although the inventive method does not provide the 5 same structural information as, for example, X-ray diffraction methods, it may be performed with a substantially smaller amount of substance and in many cases without any preceding purification and constitutes an extraordinary complement to such methods in the work of accumulating structural information 10 from unknown molecules. The method may also be used to identify changes of epitope structures, e.g., as a marker in the study of structural effects of chemical modifications.

The macromolecule or ligand is bound to the sensor surface through a biospecific ligand or chemically, whereby 15 is intended all kinds of chemical bonding, such as covalent bonding, ion bonding, dipole bonding, hydrogen bonding and van der Waal forces. Thus, the macromolecule may, e.g., be bound covalently to the surface via any suitable coupling group depending on the macromolecule studied and the sensor 20 surface used. When binding the macromolecule via a ligand the latter may be one of the ligands studied, as will be described in more detail below. By such biospecific binding of the macromolecule to the surface via a coupling group or a ligand the latter will function as a handle or spacer and place the 25 macromolecule at a certain distance from the surface, so that also epitopes near the epitope utilized to immobilize the macromolecule to the surface will be exposed and accessible for interactions with an additional ligand or additional ligands. Hereby solution conditions for the macromolecule are 30 simulated simultaneously as the advantages of a solid phase bound macromolecule may be utilized.

One embodiment of the above defined general method according to the invention comprises the steps of

- a) binding a ligand to a sensor surface,
- 35 b) permitting the macromolecule to interact with the ligand bound to the sensor surface for binding the macromolecule to the sensor surface,
- c) sequentially contacting one or more additional

ligands with the macromolecule bound to the sensor surface, and

5           d) after the contact of each additional ligand with the sensor surface carrying the macromolecule, determining the interaction of the respective ligand with the macromolecule by detecting a consequential change in the physico-chemical properties of the sensor surface.

In order to obtain additional functional/structural 10 information of macromolecules, steps c) and d) may be repeated one or more times with the various ligands added in an altered relative sequence, as will be described in more detail below. Also the binding ligand may be varied, if desired. It is also possible to repeat steps c) and d) above 15 with altered ligand order, then change the binding ligand, again alter the sequence of steps c) and d), etc.

Another embodiment of the method according to the invention comprises the steps of

20           a) binding the macromolecule to a sensor surface,  
b) sequentially contacting at least two ligands with the macromolecule bound to the sensor surface, and  
c) after the contact of each ligand with the sensor surface carrying the macromolecule, determining the interaction of the respective ligand with the macromolecule by detecting a consequential change in the physico-chemical properties of the sensor surface.

25           As in the preceding embodiment additional functional/- structural information of the macromolecule may, of course, be obtained if steps b) and c) are repeated one or more times with the various ligands added in an altered sequence.

Still another embodiment of the method according to the invention comprises the steps of

30           a) binding a ligand to a sensor surface,  
b) permitting the macromolecule to interact with at least one other ligand,  
c) contacting the macromolecule that has interacted with said at least one other ligand with the

ligand-carrying sensor surface, and

d) determining the interaction of the macromolecule with the ligand bound to the sensor surface by detecting a consequential change in the physico-chemical properties of the sensor surface.

As in the preceding embodiments additional functional-structural information of the macromolecule may be obtained if the ligand reactions are repeated one or more times with the various ligands in an altered relative sequence.

10 In a variation of the last-mentioned embodiment a sensor surface is used which has a plurality of sensing surfaces or areas, e.g. of the type described in our copending PCT-application entitled "Sensor unit and its use in biosensor systems" (based upon Swedish patent application No. 8804074-6) 15 the disclosure of which is incorporated by reference herein, each of the various ligands studied being bound to a respective sensing surface. The macromolecule having at least one of the various ligands bound thereto is then successively contacted with the multifunctional sensing surface obtained, 20 and the interaction of the macromolecule with all the sensing areas of the sensor surface is then determined for each macromolecule/ligand combination. The determination may in this case be performed with a multi-channel instrument adapted to the sensor surface, for example of the type described 25 in our copending PCT-application entitled "Optical biosensor system" (based upon Swedish patent application No. 8804075-3), the disclosure of which is incorporated by reference herein.

When a greater number of ligands are studied, the ligand 30 reaction steps in the above described embodiments may advantageously be successively performed with smaller groups of the ligands.

As will have appeared from the description furnished above the method of the invention is based upon the study of 35 functional domains (function not being limited to biofunction) of the macromolecule. On the basis of the specificity of the ligands qualitative as well as quantitative structural information about the macromolecule may be obtained. By the

sequential execution of the ligand interactions with the macromolecule the method also implies studying how the interaction of one ligand with a functional domain will affect the interaction of another functional domain with another ligand.

5 In the event of influence it may be the question of both an inhibiting and an enhancing effect on the interaction. A greater resolution may be obtained by studying affinity changes in the interaction with biosensor technique. On the basis of these studies functional information is obtained

10 from which conclusions of structural elements of the macromolecule may be drawn. With the method of the invention it is thus possible to (i) identify one or more functional/structural elements of the macromolecule and (ii) locate the latter in relation to one or more other identified structural elements.

15

The ligands used simultaneously in the method may be of the same kind, e.g. monoclonal antibodies, but may also be of two or more different kinds, e.g., both antibodies, lectins and natural ligands. An example of the first-mentioned case

20 is the mapping of antigenic epitopes on a protein by means of a set of, preferably monoclonal, antibodies, while the second case may be exemplified by the detection and location of different types of functional domains on a protein, e.g. antigenic epitopes, specific glycolysated structures and

25 active sites. In order to obtain the relative positions of the functional/structural domains the natural ligand (bio-specific partner) to the macromolecule may also be used as the ligand.

In the simplest case of carrying out the method of the

30 invention the macromolecule is studied in respect of only two ligands. In accordance with the different embodiments mentioned above, for the case that one ligand will bind to the sensing surface, the interaction determination at the sensing surface may be performed either upon the addition of the

35 other ligand after the macromolecule has first bound to the sensing surface via said first ligand, or upon the addition of the macromolecule after the second ligand has a first bound to the macromolecule. Of course, information of non-

interaction is as valuable as detected interaction. If instead other binding of the macromolecule to the sensing surface is utilized than with one of the studied ligands, the interactions of the latter will be determined in sequence, i.e. as in the first-mentioned case the second ligand may interact with the macromolecule when the first ligand has been bound to the macromolecule. If it is already known that the two ligands may interact with the macromolecule, the sequential interactions with the macromolecule will provide information of how the ligand interactions influence each other. Herefrom conclusions of the mutual relationship of the respective epitopes may be drawn. Optionally, the method steps in question may be repeated with the ligand interactions in an altered sequence. In case one ligand has first been used for binding the macromolecule to the sensing surface such reversed sequence, of course, means that the other ligand will then instead be used for binding the macromolecule to the sensing surface.

Although the above mentioned embodiment of studying the macromolecule in respect of only two ligands per se could be performed with, for example, blotting technique, ELISA or RIA (however, in a considerably more complicated and time-consuming manner), this will be practically impossible when using more ligands. It will be appreciated that in such cases the rapidity and simplicity of the method of the invention may be benefited from to a still greater extent.

As an example of the use of a plurality of ligands in the method of the invention may be mentioned the above indicated case of determining independent antigenic binding sites on a protein by means of a great number of monoclonals produced against the protein; this may be valuable, e.g., for the construction of a monoclonal-based test for the protein in question. In such a case one of the monoclonals may be used for binding the protein to the sensing surface, whereupon each one of the other monoclonals is first tested individually in respect of the protein immobilized by one of the monoclonals. This step may be said to be a repeated performance of the above described case of determination in respect

of only two ligands. Then the positively interacting monoclonals are analyzed further in various mutual combinations, e.g. in groups of five, which after one another may interact with the protein already immobilized via the original binding 5 ligand.

By this procedure it will directly appear whether a previously bound antibody blocks the binding site of a following one. Depending on the preceding interaction the antibodies will change their interactions with the epitopes in 10 question, i.e. the antigenic binding sites on the protein surface. In the ideal case the method is, of course, to be carried out such that all the antibodies are cross-tested 15 against each other. When the number of ligands is great the amount of determinations will, however, be relatively considerable, and adequate information would in practice be obtained by a suitable choice of tested ligand combinations. The monoclonals that have interacted negatively with the protein immobilized by one of the ligands are then analyzed sequentially in analogous manner but using other monoclonals 20 for the binding to the sensing surface. Optionally, the binding monoclonals may also be changed one or more times in the analysis of the positively interacting monoclonals.

After a number of monoclonal combinations has been gone through in such systematical manner, simple logic and efficient presentation of the results will permit the antibody-binding surfaces of the protein to be identified and mutually related to each other. The method just described for the characterization of a protein in respect of antibody interactions is, of course, generally applicable to all types of 30 ligands and macromolecules exhibiting a high specificity in their epitope interactions.

As will have appeared from the information furnished above an essential feature of the method of the invention is the possibility of repeating the sequential analysis of the 35 ligand interactions in loops, (i) with an altered sequence of the ligands supplied to the sensing surface, and (ii) with an altered binding site on the macromolecule, possibly in combination, to obtain improved functional/structural infor-

mation about the macromolecule. While changing the relative order of the added ligands will permit better information to be obtained of the mutual relationship of the corresponding epitopes in functional and structural respects, one may by 5 varying the binding site on the macromolecule for immobilizing it to the sensing surface during the analysis more or less rotate the macromolecule on the sensing surface. In this way all parts of the macromolecule may be efficiently exposed to ligand interaction, thereby eliminating the possible 10 influence that the proximity of an epitope to the sensing surface might have on the function of the epitope.

It will be appreciated that the method of the invention may be used for obtaining qualitative functional/structural information about a macromolecule that is completely or 15 partially unknown in this respect. The measurement principle of the method, however, also makes it possible to obtain quantitative information, e.g., where one or more epitopes of the macromolecule are previously known.

A contemplated important use of the method of the invention 20 is for studying the influence of modifications of the primary structure of a macromolecule. Hereby, for example, point mutations or deletions of peptide sequences may be accomplished and epitope mapping in accordance with the invention may then be used to demonstrate which epitopes are 25 influenced structurally such that their binding characteristics are changed. Such a modification of the macromolecular structure may be performed in order to change the properties of the molecule in one direction or another, so-called protein engineering, but also in order to obtain 30 improved structural information about a partially known macromolecule.

Another use is for locating epitopes to known units by 35 studying fragments of a macromolecule. As a further conceivable use may be mentioned the control of whether a macromolecule has been affected by a process such that an epitope has disappeared or a new epitope has been formed (neo-epitope).

The structural analysis according to this invention can

also be used for studies of macromolecules in patients serum-/plasma/blood, urine, cerebrospinal liquid, saliva or in tissue. Thus, by characterization of a macromolecule from a patient with a subset of ligands according to the present 5 method different epitope patterns or epitope densities can be disclosed in relation to sickness or pathological condition. Such difference in the structure of antigens in patients can be a result of post-translational modification such as glycosylation or proteolytic cleavage and reflect different cell 10 origin for the antigen. An example of this is the tumour-associated antigen defined by the classical monoclonal antibodies such as CA 50, CA 19-9 or CA 242. The antigen is a glycoprotein with approximately 90% carbohydrate and a core protein of about 100 KDalton in molecular weight. By the 15 method of the invention better clinical correlation may be obtained if the tumour associated antigen is characterized by a series of ligands and the binding of these different ligands is compared for epitope density and structural relations.

20 Epitope mapping is also of diagnostic interest when an immunological response to a given antigen is analyzed. By the described method and a subset of monoclonal antibodies or other ligands against defined epitopes on the antigen the immunogenic response in a patient can be analyzed by characterization of the epitopes by the ligands after binding of the patient's polyclonal antisera to the antigen. The method with sequential injections of ligands to defined epitopes after quantification of the patient's immune response will easily characterize the epitope repertoire for the patient 25 and this information can be correlated with pathological conditions and have a prognostic value. Other situations when epitope characterization with the method is of diagnostic or prognostic value are analyses of epitope immunogenic responses in patients in relation to vaccination. The epitope repertoire is of clinical interest for autoantigen as well as 30 for foreign antigen.

35 As mentioned previously the method of the invention may also, at least to some extent, be applied to impure macro-

molecule preparations. In the following will be described the use of the method according to the invention to obtain structural information about an impure antigen by means of monoclonal antibodies obtained when immunizing with the impure 5 antigen.

If, for the sake simplicity, it is assumed that the impure antigen is a mixture of the proteins A, B and C, monoclonal antibodies directed against various epitopes thereof will be obtained in the immunization. In accordance 10 with the invention one of the antibodies is bound to the sensing surface, and the protein mixture is subsequently added to biospecifically immobilize on the sensing surface the protein, say A, that the antibody bound to the sensing surface is directed against. The sensing surface obtained is 15 then used to investigate the other antibodies with regard to those binding to A. The antibodies that do not bind may be directed either against the same epitope on A as the antibody bound to the sensing surface or against protein B or C.

When an antibody binding to A has been found, the 20 protein A is instead immobilized to the sensing surface via this other antibody, and all the previously obtained antibodies which are negative against the protein A are then screened against the antibody-immobilized protein A to find those antibodies binding to the same epitope on the protein A 25 as said first antibody. The non-binding antibodies found must be directed against the protein B or C, and the above described procedure is repeated in analogous manner to identify these proteins. Once all the antibodies against the various proteins have been identified, each protein may be subjected 30 to epitope mapping in accordance with the invention as described previously. Which component is responsible for the biological effect may easily be identified by way of inhibition with the antibodies.

The sensor surface used in the method of the invention 35 may be any surface whose physical or chemical properties will be changed in a measurable manner by the ligand interactions in question. It may, for example, have a surface layer or a layer located near the surface where changes in optical

properties, such as in the emitted amount of light or the wave length thereof, refractive index, etc., may be determined. Changes in the refractive index may, e.g., be measured by the previously mentioned SPR or ellipsometry techniques.

5 The sensor surface may also be one for which the ligand interactions give rise to measurable changes in the photo-acoustic properties thereof. In other examples the biosensor surface is part of a piezoelectric crystal or field-effect transistor.

10 The total sensor system in which the sensor surface used in the method of the invention is included will, of course, depend on the kind of the sensor surface and the surface parameter studied. A suitable sensor system based upon SPR technique is described in our aforesaid copending PCT-application entitled "Optical biosensor system". The more detailed design thereof will appear from the following example.

15 Optionally the information obtained in the method of the invention may be computer processed to simplify the interpretation of the surface characteristics of the macromolecule in question, and the result may advantageously be presented in graphical form.

20 The invention will be further illustrated in the following example. In connection herewith reference is made to accompanying drawings, in which

25 Fig. 1a and 1b are graphs showing the surface change responses obtained when performing different steps of one embodiment of the method of the invention;

30 Fig. 2a and 2b are similar graphs as Fig. 1a and 1b showing the surface change responses obtained in another embodiment of the method of the invention; and

Fig. 3 is an example of a schematic graphical illustration of the information obtained by the method of the invention.

#### EXAMPLE

35 In this example will be described epitope mapping of HIV-protein P24 by means of the method according to the invention. This protein is at present of very great interest,

since the presence of the protein itself or antibodies directed against it is considered to be an early indication of HIV-infection. For the construction of a test system it is, of course, important to know several independent binding 5 sites on the protein.

For the epitope mapping an optical biosensor system described in our aforesaid PCT-application entitled "Optical biosensor system" was used. This biosensor system, which in one embodiment is based upon SPR technology known per se, has 10 a replaceable sensor unit; a block unit for liquid handling having a conduit or channel system which transports the reagent and sample solutions over the sensing surface of the sensor unit; an optical unit which couples incident light rays to the sensitized surface and detects the reflected 15 radiation; and an evaluation unit which after calibration transforms the detector signal into a parameter proportional to the amount of substance at the sensing surface. When performing a measurement a defined sample liquid volume is introduced by injection into a defined channel section, which 20 liquid volume is then by means of eluent liquid forced to pass the sensing surface for optical analysis. The instrument used here had a measuring channel of 0.5 x 0.05 x 4 mm. As pump was used a modified variation of the pump marketed by 25 Pharmacia AB, Sweden, under the designation P500. An auto-injector Gilson Model 231 with a 50  $\mu$ l extern loop was coupled to the instrument.

The sensor unit consisted of a glass plate coated with a thin gold film to which had been bound a layer of dextran hydrogel as described in our copending PCT-application entitled 30 "Sensing surfaces capable of selective biomolecular interactions to be used in biosensor systems" (based upon Swedish patent application No. 8804073-8), the disclosure of which is incorporated by reference herein, and which then had been modified as described in our aforesaid copending PCT-application entitled "Sensor unit and its use in biosensor 35 systems" and is specified below.

The detector device comprised a set of detector elements in the form of photo-diodes having a width of 80  $\mu$  and spaced

at 20  $\mu$  intervals. The unit "diode(s)" used hereinafter for the mass adsorption at the measuring surface (the response) is associated to this particular photo-diode arrangement and indicates the number of successive photo-diodes embraced by 5 the resonance change in angle caused by the refractive index change of the sensing surface.

For the determination protein P24 obtained by recombinant DNA technique as well as 54 culture media containing anti-P24 monoclonals with reactivity against this protein 10 were used.

Prior to the actual epitope determination subclass and concentration determination on these 54 culture media were performed as will be described below.

As the eluent was used 10 mM Hepes, 0.15 NaCl, 3.4 mM 15 EDTA, 0.1% FT 229, pH = 7.4. Reagent and sample were injected in volumes of 20  $\mu$ l, and regeneration was performed with 0.1 M glycine-HCl, pH = 2.5, 0.1% FT 229 (20  $\mu$ l).

#### A. Subclass determination

For this determination the dextran treated sensing 20 surface was modified by carboxymethylation, and reactive ester groups were subsequently introduced by incubation with N-hydroxysuccinimide and N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride (EDC). To the sensing surface derivatized in this way rabbit anti-mouse light chains from 25 an immunosorbent-purified preparation were coupled.

The following anti-mouse IgG-subclass reagents were used:

Rat monoclonal anti-G1, rat monoclonal anti-G2a, rat 30 monoclonal anti-G2b and rat monoclonal anti-G3 obtained from MIAB, Uppsala, Sweden. The reagents were diluted to 100  $\mu$ g/ml in 10 mM Hepes, pH = 7.4.

The 54 culture media were successively analyzed, the anti-subclass reagents being run sequentially in the order anti-G3, anti-G2a, anti-G2b and anti-G1. The flow was 20  $\mu$ l/- 35 min, and the time between the injections was 2 minutes.

A culture medium was defined as G1 when the response for anti-G1 amounted to at least 0.1 diode. All culture media except No. 8, 51, 27, 35, 38, 39, 40, 41, 43 and 46 exhibited

response values exceeding 0.1. The response for anti-G3, anti-G2a and anti-G2b did not exceed 0.02 diode for any culture medium. The injection of purified IgM (100  $\mu$ g/ml) resulted in responses less than 0.03 for all anti-subclass reagents.

5        **B. Concentration determination**

All culture media were correlated to a G1-based standard curve established on the basis of response values obtained with a mix of G1-monoclonals (anti-beta-2-microglobulin) 10 diluted in culture medium (5% FCS) to the concentrations 2, 5, 10, 20, 30, 40, 50, 60, 80 and 100  $\mu$ g/ml, respectively.

The standard points were run in duplicate, and a standard curve based upon the mean value of each point was established in the interval 2-30  $\mu$ g/ml. The same sensing surface 15 as in the subclass determination above was used; the flow was 20  $\mu$ l/min. and the time between the injections was 3 minutes. The measurements on the culture media were performed with single samples. The culture media 8, 27, 35, 38, 40 and 41 showed very low concentrations.

20        **C. Epitope studies**

On the basis of the above performed subclass and concentration determinations the following culture media were excluded from the epitope studies: 8, 16, 27, 35, 38, 39 and 25 40. The other culture media were characterized in respect of mutual epitope reactivity as will be described below. For these determinations the dextran treated sensing surface was modified as follows:

30        **C1. Introduction of hydrazide functions**

35        3.5 g bromoacetic acid were dissolved in 27 g of 2 M sodium hydroxide solution. The mixture was poured over a dextran-treated and carboxymethylated sensor surface and incubated for 16 hours at 25°C in a shaker incubator. The surface was washed with water, whereupon the aforesaid procedure was repeated once. After washing, the surface was treated for 5 minutes with 0.8 g of N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride (EDC) in 20 ml of water,

this being then followed by an addition of 4.0 ml of hydrazine hydrochloride in 20 ml of water. The surface was incubated for 16 hours in a shaker incubator at 25°C and then washed with water.

5    C2. Coupling of rabbit-anti-mouse-Fcγ to the derivatized measuring surface

10    Immunosorbent-purified rabbit anti-mouse-Fcγ in 10 mM acetate buffer, pH 5.5, was coupled during 20 minutes to the hydrazide surface obtained above, whereupon unbound antibody was removed by rinsing the surface in PBS buffer, pH 7.4, and in 0.1 M glycine, pH 2.5. The coupling obtained corresponded to a response in the measuring equipment of about 2.5 diodes.

A flow of 20 µl/min. and 3 min. between the injections were used for the experiment.

15    C3. Epitope mapping

As a first step culture medium No. 12 (diluted 1:4) was injected to immobilize the corresponding monoclonal on the sensing surface. To block any remaining binding sites on the sensing surface a G1-monoclonal irrelevant in the context, viz. anti-beta-2-microglobulin (40 µg/ml), was then injected, whereupon the HIV-protein P24 (10 µg/ml) was injected. This protein bound biospecifically to the surface via the monoclonal 12, and the system was then ready for analysis of interaction with the other monoclonals. In a first analysis series the binding of each monoclonal individually was studied with regeneration of the system between each measurement.

As the result the culture media were distributed among two groups:

a) those reacting with P24 independently of medium No.

30    12: 1, 17, 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33, 34, 36, 37, 41, 43, 44, 45, 47, 48, 49, 50, 51, 52, 53 and 54; and

b) those not reacting with P24 when medium No. 12 has bound: 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 35    18 and 42.

Case a) above is illustrated in the accompanying Fig. 1a

and case b) in Fig. 1b where the y-axis shows relative response and the x-axis the time in seconds. In both figures the numeral 1 indicates the injection of culture medium No. 12 (for technical reasons the injection was made last in each 5 cycle; no regeneration was then made, and the monoclonal was therefore already bound to the surface when injection No. 2 was performed); 2 indicates the injection of anti-beta-2-microglobulin, 3 indicates the injection of P24, 4 indicates the injection of P24-reactive culture medium that binds to 10 P24 independently of medium No. 12 (Fig. 1a) or that competes with medium No. 12 (Fig. 1b), and 5 indicates regeneration. In the measurements a positive response is defined as a diode reading greater than 0.13 diode, but a negative signal must not exceed 0.02 diode.

15 The positive media were then analyzed further in various mutual combinations, several media being injected sequentially. The various combinations and the results obtained are shown in Table 1 below. In the table the responses exceeding 0.13 diode are indicated by "+". A response below 0.02 diode 20 is designated by "-". In certain cases the response is between the two existing limits (half +).

Table 1

"12+"-clones tested against clone 12

25	Medium		Medium		Medium	
	No.	Response	No.	Response	No.	Response
	1)	1	+	2)	1	+
		17	+		1	-
		19	+	21	-	
30	20	+			22	+
	21	-			23	+
	4)	23	+	5)	25	+
		24	+		26	-
		25	-	6)	23	+
35	26	-			26	-
	22	-			25	+
	7)	28	+	8)	29	+
		29	+		30	-
		30	-	9)	33	+
40	31	-			34	+
	32	-			36	? *
					37	-
					41	-

\* sweep error

Table 1 (cont.)

		Medium		Medium		Medium			
		No.	Response	No.	Response	No.	Response		
5	10)	36	+	11)	37	+	12)	41	+
		33	+		41	+		36	-
		34	+		36	-		33	+
					33	-		37	-
					34	+			
10	13)	43	+	14)	44	+	15)	49	+
		44	+		45	-		50	+
		45	-		48	+		51	+
		47	+		47	-		52	-
		48	-					53	-
15	16)	51	+	17)	53	+	18)	54	+
		52	+		51	+		53	+
		53	-		52	-		51	-
		50	-		54	-			
		49	+						
20	19)	1	+	20)	22	+	21)	29	+
		22	+		43	+		22	-
		28	+		17	+		43	-
		33	+		29	-			
		43	+		34	+			
25	22)	17	+	23)	22	+	24)	19	+
		29	+		43	+		36	-
		43	-		19	-		22	-
		22	-		36	-		43	-
					49	+		49	+
30	25)	22	+	26)	43	+	27)	29	+
		19	half	19	half	+		19	-
		43	-		22	-			
	28)	49	+	29)	20	+	30)	23	+
		43	+		43	+		43	+
35		34	+		34	+		34	+
		17	+		17	+		17	+
		22	+		22	+		22	+
40	31)	44	+	32)	47	+	33)	20	+
		43	+		43	+		23	+
		34	+		34	+		44	+
		17	+		17	-		50	-
		22	-		22	+			
45	34)	50	+	35)	1	+	36)	28	+
		23	+		43	+		43	+
		44	-		34	+		34	+
		20	+		17	+		17	+
					22	+		22	+
50	37)	33	+	38)	51	+	39)	49	+
		43	+		43	+		1	-
		34	+		34	+		28	+
		17	+		17	+		33	-
		22	+		22	+		20	-

Table 1 (cont.)

Medium			Medium			Medium		
	<u>Medium</u> <u>No.</u>	<u>Response</u>		<u>Medium</u> <u>No.</u>	<u>Response</u>		<u>Medium</u> <u>No.</u>	<u>Response</u>
5	40)	1	+	41)	20	+	42)	23
	49	-		49	-		1	+
	33	+		28	+		33	+
							28	-
10	43)	20	+	44)	51	+		
	33	-		1	+			
				33	+			
				28	-			

Fig 2a and 2b, respectively, show the detector response in such an experiment where 5 monoclonals were sequentially injected and all of them bind independently of the fact that the preceding monoclonal has bound. In Fig. 2b the first and the second monoclonals are bound (+), while the other binding sites for the other three monoclonals are blocked (-).

The negative media were analyzed in analogous manner as the positive media but with medium No. 30 immobilized in the first step instead of medium No. 12. In an initial experiment it was verified that the individual media reacted with a positive response, medium No. 12 and medium No. 42 reacting with a response outside the limits set. These two media were analyzed with the same result in a sequence with medium No. 34 immobilized in the first step. The media were then analyzed in the combinations and with the results indicated in Table 2 below. The same judgement criteria apply as for Table 1 above.

Table 2

"12--"clones tested against clone 30

Medium			Medium			Medium		
	<u>Medium</u> <u>No.</u>	<u>Response</u>		<u>Medium</u> <u>No.</u>	<u>Response</u>		<u>Medium</u> <u>No.</u>	<u>Response</u>
35	1)	14	+	2)	2	+	3)	15
	2	half+		3	-		6	-
	3	-		4	-		7	-
	4	-		5	-		9	-
40	5	-		14	-		10	-
	4)	18	+	5)	42	half+	6)	18
	11	-		14	half+		15	-
	12	-		15	half+		2	-
45	13	-		18	-			
	42	-						

"12--clones tested against clone 34

		Medium No.	Response	Medium No.	Response
5	7)	42	half+	8)	3
		14	half+		18
		15	half+		10
					6
					2

10 When all the results had been compiled the characterization performed could diagrammatically be illustrated as is shown in Fig. 3. When the culture medium number in the figure is underlined it indicates that the medium was tested against all other underlined media. As appears from Fig. 3 six major 15 domains containing independent binding sites could thus be identified. It is to be noted that the characterization is incomplete since all individual media were not tested against all the others. This may result in certain media having their reactivity directed against a very close but not identical 20 epitope.

The above described epitope studies revealed a surprisingly great number of epitopes on the P24 molecule and that there is simultaneously room for at least 6 antibodies thereon. The result of the studies may, for example, be used 25 for the development of suitable monoclonal combinations for diagnostic tests.

The invention is, of course, not restricted to the embodiments particularly described above, but many modifications and changes are within the scope of the general inventive concept as it is defined in the subsequent claims.

Claims

1. A method of characterizing a macromolecule by studying its interactions with ligands, characterized in that it comprises determination of the mutual influence of ligand interactions by, after the macromolecule has interacted with at least one ligand, contacting the macromolecule with at least one additional ligand, either the macromolecule or the additional ligand(s) having been bound to a sensor surface, determining interaction by detecting a consequential change in the physico-chemical properties of the sensor surface, and on the basis of the determined mutual dependence between the ligand interactions discriminating between epitopes of the macromolecule and mapping their relative positions.
- 15 2. A method according to claim 1, characterized in that it comprises the steps of
  - a) binding the macromolecule to a sensor surface,
  - b) sequentially contacting at least two ligands with the macromolecule bound to the sensor surface, and
  - 20 c) after the contact of each ligand with the sensor surface carrying the macromolecule, determining the interaction of the respective ligand with the macromolecule by detecting a consequential change in the physico-chemical properties of the sensor surface.
- 25 3. A method according to claim 1, characterized in that it comprises the steps of
  - a) binding a ligand to a sensor surface,
  - b) permitting the macromolecule to interact with the ligand bound to the sensor surface for binding the macromolecule to the sensor surface,
  - 30 c) sequentially contacting one or more additional ligands with the macromolecule bound to the sensor surface, and
  - d) after the contact of each additional ligand with

the sensor surface carrying the macromolecule, determining the interaction of the respective ligand with the macromolecule by detecting a consequential change in the physico-chemical properties of the sensor surface.

4. A method according to claim 1, characterized in that it comprises the steps of

- a) binding a ligand to a sensor surface,
- b) permitting the macromolecule to interact with at least one other ligand,
- c) contacting the macromolecule that has interacted with said at least one other ligand with the ligand-carrying sensor surface, and
- d) determining the interaction of the macromolecule with the ligand bound to the sensor surface by detecting a consequential change in the physico-chemical properties of the sensor surface.

5. A method according to any one of claims 1-4, characterized in that it comprises repeating at least two of the ligand interactions with the ligands in an altered sequence.

6. A method according to claims 2 and 5, characterized in that steps b) and c) are repeated one or more times with the ligands in an altered sequence.

25 7. A method according to claims 3 and 5, characterized in that steps c) and d), and optionally also a), are repeated one or more times with the ligands in an altered sequence.

30 8. A method according to claims 4 and 5, characterized in that steps a) - d) are repeated one or more times with the ligands in an altered sequence.

9. A method according to any one of the preceding claims,

wherein a plurality of ligands is used, characterized in that the method is performed repeatedly with smaller groups of the ligands.

10. A method according to claim 4,  
5 characterized in that each one of a plurality of ligands is bound to a respective sub-region of the sensor surface and that the macromolecule having at least one ligand bound thereto is successively contacted with the multi-functional sensor surface obtained, the interaction of the macromolecule  
10 with all of said sub-regions of the sensor surface being determined for each macromolecule/ligand combination.
11. A method according to any one of the preceding claims, characterized in that said change in the physico-chemical properties of the sensor surface is a change in the refractive index of the sensor surface.  
15
12. A method according to any one of the preceding claims, characterized in that the macromolecule is a protein.
13. A method according to any one of the preceding claims, characterized in that the ligands comprise antibodies.  
20
14. A method according to any one of the preceding claims, characterized in that the number of ligands is at least three.
15. The use of the method according to any one of claims 1-14 for studying the influence of a structural modification of  
25 a macromolecule upon the ligand binding properties thereof.
16. The use of the method according to any one of claims 1-14 for diagnostic or prognostic clinical purposes.
17. The use according to claim 16,  
30 characterized by characterizing the macromolecule or a complex thereof with a subset of ligands defining different

possible epitopes on the macromolecule, the presence or absence, respectively, of one or more of said epitopes on the macromolecule being indicative of a pathological condition.

18. The use according to claim 16 for analyzing immune response by first contacting a macromolecule having defined epitopes with a patient sample, and then determining the possible blocking of one or more of the epitopes by macromolecules present in the sample by contacting the macromolecule with a subset of ligands binding to said epitopes.

1/3




FIG. 1a




FIG. 1b

2/3




FIG. 2a




FIG. 2b

3/3




FIG. 3

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/SE 89/00644

## I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) \*

According to International Patent Classification (IPC) or to both National Classification and IPC  
**IPC5: G 01 N 33/543**

## II. FIELDS SEARCHED

Minimum Documentation Searched 7

Classification System	Classification Symbols
IPC5	G 01 N
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *	

SE,DK,FI,NO classes as above

## III. DOCUMENTS CONSIDERED TO BE RELEVANT\*

Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	Chemical Abstracts, volume 109, no. 19, 7 November 1988, (Columbus, Ohio, US), Bataillard Pierre et al : "Direct detection of immunospecies by capacitance measurements.", see page 360, abstract 166540v, & Anal. Chem. 1988, 60(21), 2374- 9	1-4, 12-18
Y	US, A, 4659678 (G.C. FORREST ET AL.) 21 April 1987, see the whole document and particularly the claims and example 1	1-4, 12-18
A.	Bull. Chem. Soc. Jpn., Vol. 61, January 1988 E. Katchalski-Katzir et al: "Use of Monoclonal Antibodies in the Study of the Conformation and Conformational Alterations in Proteins", see page 133 - page 139	1

\* Special categories of cited documents: <sup>10</sup>

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search  
**5th February 1990**

Date of Mailing of this International Search Report

**1990-02-07**

International Searching Authority

**SWEDISH PATENT OFFICE**

Signature of Authorized Officer

*Carl-Olof Gustafsson*

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	EP, A2, 0311768 (CHIMICRON CORPORATION) 19 April 1989, see fig. 5A-E and col. 5-9 --	1,3,4, 12,13, 16
X	EP, A2, 0142301 (SERONO DIAGNOSTICS LIMITED) 22 May 1985, see page 2, lines 28-34, page 4, line 15 - page 5 and page 7, lines 16-27 --	1,3,4
X	EP, A2, 0167248 (SERONO DIAGNOSTICS LIMITED) 8 January 1986, see the whole document and in particular page 7, line 21 - page 13, line 12 and page 15 lines 17-26 --	1,3,4, 12,13, 15,16
X	EP, A1, 0276142 (ARES-SERONO RESEARCH & DEVELOPMENT LIMITED PARTNERSHIP) 27 July 1988, see example 1 and page 6 --	1,4,11- 13
X	EP, A2, 0276968 (YELLOWSTONE DIAGNOSTICS CORPORATION) 3 August 1988, see col. 14 - col. 15, line 49 --	1,4,11- 13
A	EP, A1, 0184600 (BATTELLE MEMORIAL INSTITUTE) 18 June 1986, see pages 4-9 and examples 5 and 6 --	1,11- 13

**ANNEX TO THE INTERNATIONAL SEARCH REPORT**  
**ON INTERNATIONAL PATENT APPLICATION NO. PCT/SE 89/00644**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A- 4659678	21/04/87	EP-A-B- 0105714		18/04/84
		AU-D- 19648/83		05/04/84
		AU-A- 564383		13/08/87
		CA-A- 1226215		01/09/87
		DE-A- 3377531		01/09/88
EP-A2- 0311768	19/04/89	JP-A- 1145560		07/06/89
EP-A2- 0142301	22/05/85	AU-D- 34651/84		02/05/85
		JP-A- 60127450		08/07/85
		CA-A- 1223922		07/07/87
		AU-A- 575595		04/08/88
EP-A2- 0167248	08/01/86	AU-D- 42411/85		09/01/86
EP-A1- 0276142	27/07/88	AU-D- 10631/88		28/07/88
		JP-A- 63271162		09/11/88
EP-A2- 0276968	03/08/88	AU-D- 10995/88		04/08/88
		JP-A- 63277969		15/11/88
EP-A1- 0184600	18/06/86	AU-D- 50867/85		19/06/86
		JP-A- 61191965		26/08/86
		US-A- 4818710		04/04/89
		AU-A- 582604		06/04/89